Cancer Models on Chip: Paving the Way to Large‐Scale Trial Applications
Source abstract
Abstract
Abstract Cancer kills millions of individuals every year all over the world (Global Cancer Observatory). The physiological and biomechanical processes underlying the tumor are still poorly understood, hindering researchers from creating new, effective therapies. Inconsistent results of preclinical research, in vivo testing, and clinical trials decrease drug approval rates. 3D tumor‐on‐a‐chip (ToC) models integrate biomaterials, tissue engineering, fabrication of microarchitectures, and sensory and actuation systems in a single device, enabling reliable studies in fundamental oncology and pharmacology. This review includes a critical discussion about their ability to reproduce the tumor microenvironment (TME), the advantages and drawbacks of existing tumor models and architectures, major components and fabrication techniques. The focus is on current materials and micro/nanofabrication techniques used to manufacture reliable and reproducible microfluidic ToC models for large‐scale trial applications.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Innovative Microfluidic and Catalytic Techniques Innovation · Cancer Cells and Metastasis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Centre for Rapid and Sustainable Product Development Polytechnic of Leiria Marinha Grande 2430‐028 Portugal
INESC Microsistemas e Nanotecnologias (INESC MN) Rua Alves Redol 9 Lisbon 1000‐029 Portugal
TEMA Mechanical Engineering Department University of Aveiro Aveiro 3810‐193 Portugal
Polytechnic Institute of Coimbra Applied Research Institute Coimbra 3045‐093 Portugal
Department of Physics Instituto Superior Técnico Lisbon 1049‐001 Portugal
Associate Laboratory Institute for Health and Bioeconomy – i4HB Lisbon Portugal
Intelligent Systems Associate Laboratory (LASI) Aveiro 3810‐193 Portugal
Department of Biomedical Engineering University Medical Center Groningen University of Groningen Groningen 9713 AV The Netherlands
W.J. Korf Institute for Biomedical Engineering and Materials Science University Medical Center Groningen University of Groningen Groningen 9713 AV The Netherlands
Drug Research Program Division of Pharmaceutical Chemistry and Technology Faculty of Pharmacy University of Helsinki Helsinki 00014 Finland
Funding
Fundação para a Ciência e a Tecnologia · Academy of Finland · European Association of National Metrology Institutes
References (100+)
Show source-provided references
1. International Agency for Research on Cancer “Cancer Tomorrow ”https://gco.iarc.fr/tomorrow/en accessed: May 2022.
2. 10.1038/nature0978110.1038/nature09781 ↗
3. 10.1038/s41586-021-04224-510.1038/s41586-021-04224-5 ↗
4. 10.1038/s41467-017-01027-z10.1038/s41467-017-01027-z ↗
5. 10.1038/s41540-022-00219-810.1038/s41540-022-00219-8 ↗
6. 10.1126/sciadv.abi590410.1126/sciadv.abi5904 ↗
7. 10.1038/s41586-019-1907-710.1038/s41586-019-1907-7 ↗
8. 10.1038/s41416-020-0799-510.1038/s41416-020-0799-5 ↗
9. 10.1038/s41392-020-0134-x10.1038/s41392-020-0134-x ↗
10. 10.1038/nm146910.1038/nm1469 ↗
11. 10.1002/cam4.247410.1002/cam4.2474 ↗
12. 10.1186/s12964-020-0530-410.1186/s12964-020-0530-4 ↗
13. 10.1016/j.trecan.2020.10.00910.1016/j.trecan.2020.10.009 ↗
14. 10.1016/j.trecan.2021.06.00910.1016/j.trecan.2021.06.009 ↗
15. 10.1016/j.brainres.2019.14639310.1016/j.brainres.2019.146393 ↗
16. 10.1038/s41467-018-03705-y10.1038/s41467-018-03705-y ↗
17. 10.1016/j.trecan.2018.02.00810.1016/j.trecan.2018.02.008 ↗
18. 10.1038/s41563-020-0755-z10.1038/s41563-020-0755-z ↗
19. 10.1021/acs.chemrev.6b0036910.1021/acs.chemrev.6b00369 ↗
20. 10.1158/0008-5472.CAN-18-396210.1158/0008-5472.CAN-18-3962 ↗
21. 10.1002/ctm2.30810.1002/ctm2.308 ↗
22. Arneth B. · Med · 2020 · 56 · 15
23. 10.1038/s41392-020-0178-y10.1038/s41392-020-0178-y ↗
24. 10.1242/jcs.11639210.1242/jcs.116392 ↗
25. 10.1016/j.cub.2020.06.08110.1016/j.cub.2020.06.081 ↗
26. 10.1016/j.canlet.2019.07.01010.1016/j.canlet.2019.07.010 ↗
27. 10.1038/nrm390410.1038/nrm3904 ↗
28. 10.3390/ijms2205255010.3390/ijms22052550 ↗
29. 10.1016/j.csbj.2018.07.00310.1016/j.csbj.2018.07.003 ↗
30. 10.1016/j.devcel.2020.06.01810.1016/j.devcel.2020.06.018 ↗
31. 10.1016/j.cell.2015.08.01610.1016/j.cell.2015.08.016 ↗
32. 10.1186/s40164-022-00277-y10.1186/s40164-022-00277-y ↗
33. 10.1186/s40164-022-00363-110.1186/s40164-022-00363-1 ↗
34. 10.1038/s41556-018-0131-210.1038/s41556-018-0131-2 ↗
35. 10.1016/j.plrev.2023.01.01710.1016/j.plrev.2023.01.017 ↗
36. 10.3389/fcell.2018.0001710.3389/fcell.2018.00017 ↗
37. 10.18632/oncotarget.2773610.18632/oncotarget.27736 ↗
38. 10.1126/science.aaz086810.1126/science.aaz0868 ↗
39. 10.1038/s41378-021-00277-810.1038/s41378-021-00277-8 ↗
40. 10.3389/fmolb.2020.0003310.3389/fmolb.2020.00033 ↗
41. 10.1186/s12935-019-0733-110.1186/s12935-019-0733-1 ↗
42. 10.2174/092986732566618060512263310.2174/0929867325666180605122633 ↗
43. 10.3390/cancers1304087410.3390/cancers13040874 ↗
44. 10.1038/s41563-021-01057-510.1038/s41563-021-01057-5 ↗
45. 10.1038/nbt.159510.1038/nbt.1595 ↗
46. 10.3389/fbioe.2021.66050210.3389/fbioe.2021.660502 ↗
47. 10.1002/adhm.20180136310.1002/adhm.201801363 ↗
48. 10.1016/j.msec.2019.11026410.1016/j.msec.2019.110264 ↗
49. 10.3390/cancers1401019010.3390/cancers14010190 ↗
50. 10.1038/s41568-018-0104-610.1038/s41568-018-0104-6 ↗
51. 10.1016/j.jconrel.2021.04.02410.1016/j.jconrel.2021.04.024 ↗
52. 10.3389/fimmu.2020.60364010.3389/fimmu.2020.603640 ↗
53. 10.3389/fbioe.2016.0001210.3389/fbioe.2016.00012 ↗
54. 10.1517/17460441.2012.70833410.1517/17460441.2012.708334 ↗
55. 10.3390/bios1111044510.3390/bios11110445 ↗
56. 10.1186/s12935-021-01853-810.1186/s12935-021-01853-8 ↗
57. 10.1016/j.jconrel.2020.04.02510.1016/j.jconrel.2020.04.025 ↗
58. 10.1186/s13045-022-01322-310.1186/s13045-022-01322-3 ↗
59. 10.1038/s43018-020-0102-y10.1038/s43018-020-0102-y ↗
60. 10.3390/polym1307110510.3390/polym13071105 ↗
61. 10.1016/j.mtcomm.2019.10065110.1016/j.mtcomm.2019.100651 ↗
62. 10.1002/jbm.b.3455410.1002/jbm.b.34554 ↗
63. 10.1016/j.bioactmat.2021.02.00410.1016/j.bioactmat.2021.02.004 ↗
64. 10.1016/j.trsl.2021.11.00810.1016/j.trsl.2021.11.008 ↗
65. 10.1002/adhm.20220069010.1002/adhm.202200690 ↗
66. 10.1038/s41698-020-0121-210.1038/s41698-020-0121-2 ↗
67. 10.3390/ma1218294510.3390/ma12182945 ↗
68. 10.1016/j.cobme.2018.03.00410.1016/j.cobme.2018.03.004 ↗
69. 10.1021/acs.chemrev.8b0004210.1021/acs.chemrev.8b00042 ↗
70. 10.1002/ame2.1210210.1002/ame2.12102 ↗
71. 10.1111/j.1476-5381.2010.00922.x10.1111/j.1476-5381.2010.00922.x ↗
72. 10.1016/j.isci.2020.10171910.1016/j.isci.2020.101719 ↗
73. 10.1016/j.addr.2021.04.01810.1016/j.addr.2021.04.018 ↗
74. 10.3390/cancers1303045210.3390/cancers13030452 ↗
75. 10.3390/cells806062110.3390/cells8060621 ↗
76. 10.3390/ijms1901018110.3390/ijms19010181 ↗
77. 10.1002/smll.20200418210.1002/smll.202004182 ↗
78. 10.1007/s10439-020-02498-w10.1007/s10439-020-02498-w ↗
79. Moghimi N. · Int. J. Bioprint. · 2022 · 2810.1016/j.bprint.2022.e00238 ↗
80. 10.1016/S0092-8674(00)81683-910.1016/S0092-8674(00)81683-9 ↗
81. 10.1126/science.165974210.1126/science.1659742 ↗
82. 10.1016/j.ebiom.2021.10330310.1016/j.ebiom.2021.103303 ↗
83. 10.1039/D0LC00799D10.1039/D0LC00799D ↗
84. 10.7150/thno.7176110.7150/thno.71761 ↗
85. 10.3390/cancers1316419210.3390/cancers13164192 ↗
86. 10.1016/j.radonc.2021.01.01810.1016/j.radonc.2021.01.018 ↗
87. 10.1088/1758-5090/ab97c010.1088/1758-5090/ab97c0 ↗
88. 10.3389/fbioe.2022.84067410.3389/fbioe.2022.840674 ↗
89. 10.1007/s10529-018-2611-710.1007/s10529-018-2611-7 ↗
90. 10.1016/j.apmt.2020.10065610.1016/j.apmt.2020.100656 ↗
91. 10.1016/j.ijbiomac.2019.04.19710.1016/j.ijbiomac.2019.04.197 ↗
92. 10.1126/sciadv.abg528310.1126/sciadv.abg5283 ↗
93. 10.1007/s10529-020-03043-410.1007/s10529-020-03043-4 ↗
94. 10.1039/D1LC00182E10.1039/D1LC00182E ↗
95. 10.1002/adfm.20180717310.1002/adfm.201807173 ↗
96. 10.1186/s12967-017-1328-z10.1186/s12967-017-1328-z ↗
97. 10.3390/cancers1415369210.3390/cancers14153692 ↗
98. 10.1177/175883401351741410.1177/1758834013517414 ↗
99. 10.1016/j.addr.2018.06.00110.1016/j.addr.2018.06.001 ↗
100. Johnson A. · Cell. Mol. Bioeng. · 2022 · 1